News & Updates

The oral small-molecule TLR7/8 inhibitor enpatoran has shown a dose-dependent effect on disease activity in patients with active skin manifestations of cutaneous lupus erythematosus (CLE) or systemic lupus erythematosus (SLE) in the phase II WILLOW trial.

In a recent study from Singapore, housing type and sedentary behaviour have emerged as novel risk factors for diabetic peripheral neuropathy.

The use of invasive intracranial pressure monitoring (IICPM) in three high-volume liver transplant centres has declined over 10 years with no associated worsening of outcomes among patients with acute liver failure (ALF), according to a study.

Racial and ethnic discriminations appear to result in greater patient-reported disease activity, pain, fatigue, depression, and anxiety among patients with systemic lupus erythematosus (SLE), a recent study has shown.

In the treatment of patients with covert hepatic encephalopathy, use of rifaximin results in improved cognitive performance and decreased cirrhosis-related adverse events, as shown in an open-label study.

Adding nipocalimab to standard-of-care (SoC) demonstrates sustained disease control through week 120 in adult patients with antibody-positive generalized myasthenia gravis (gMG), including anti-AChR* or anti-MuSK**, according to the Vivacity-MG3 open-label extension (OLE) study presented at AAN 2026.